Brind.

Schrödinger's SGR-1505 was designated as a Fast Track product by the FDA, accompanied by an Equalweight rating from Morgan Stanley.

3 reports, 1 independent Updated Jul 10

Gone quiet

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Schrödinger's SGR-1505 was designated as a Fast Track product by the FDA, accompanied by an Equalweight rating from Morgan Stanley.

Who's involved

What this event is mainly about

FDA Schrödinger

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Schrödinger
American life sciences company

Nothing else this week.

Related events

FDA granted Fast Track designation to NRX-100 on September 4, 2025.Jun 7

Coverage

Newest first; wire copies grouped

Jul 10Insider MonkeyMorgan Stanley Assumes Coverage on Schrödinger (SDGR) Stock Schrödinger, Inc. (NASDAQ:SDGR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Morgan Stanley assumed cov
Jul 4Unknown outlet
Jun 27Unknown outlet